With the normalization of national centralized procurement, provincial and even cross regional alliance centralized procurement has become a must for pharmaceutical enterprises. According to the statistics of the Ministry of Commerce, the total drug sales in Shandong Province reached 114.399 billion yuan in 2017, and the purchase amount of 40 varieties included in the first batch of procurement with quantity reached 5 billion yuan in 2019.
For the above-mentioned centralized purchasing market, according to the medical insurance bureaus medical price and bidding credit evaluation system, and based on the business contract relationship, medical institutions are guided or required to purchase pharmaceutical products from honest enterprises, and reduce or stop purchasing pharmaceutical products from dishonest enterprises.
Zhou Shu, a pharmaceutical strategic consultant, told the China times that the punishment of the blacklist pharmaceutical enterprises in improving the trading conditions of centralized purchase by the pharmaceutical price and bidding credit evaluation system is not only to crack down on the commercial bribery and gold sales of pharmaceutical enterprises, but also to promote the pharmaceutical enterprises to reduce costs, innovate marketing, and pull the pharmaceutical industry back to the track of compliance and innovation.
Those who lose faith lose their talent
Due to the intense price competition of centralized procurement with quantity, pharmaceutical companies may be squeezed out of the competition within a fraction of the quotation. Before this, when the first national centralized purchase of coronary stents fell by an astonishing rate, the industry had outflow the view that manufacturers were even lower than the cost quotation only to keep the market share.
In the detailed rules on credit rating of pharmaceutical enterprises released this time, bidding with quotation lower than cost, bidding by fraud, collusion bidding, abuse of market dominant position, etc., disturbing the order of centralized procurement was listed in the list of dishonest projects.
Pharmaceutical enterprises that participate in or are entrusted to participate in the centralized procurement of drugs and medical consumables and platform networking should make a written promise of keeping faith, otherwise they will not be qualified to participate in the centralized purchase.
Since August 28, pharmaceutical enterprises and their employees, entrusted agent enterprises, etc., have been prosecuted according to law due to pharmaceutical commercial bribery, monopoly behavior, price and tax related violations, etc., or the bribery objects have been held accountable according to law (including the cases in which illegal facts are identified but no prosecution or punishment is decided), so they need to provide specific information to provincial centralized purchasing agencies.
Taking pharmaceutical commercial bribery as an example, the reported information includes but is not limited to the product and amount involved, the cause of action and judgment result, the enterprise and personnel involved, etc. If commercial bribery is involved, the rebate of drugs or medical consumables involved in the case shall be described in detail, including the object, amount, method and source of funds, and the proportion of rebate of single drug or medical consumables in the retail price, etc.
Pharmaceutical enterprises dishonesty rating will be divided into general, medium, serious and particularly serious. Once listed as serious and particularly serious pharmaceutical enterprises, according to the corresponding provisions of the discretionary benchmark, their products will be disqualified from the network, bidding and distribution. At the same time, in addition to the provincial punishment measures, they will be listed Serious and especially serious enterprises will also be jointly disposed of by the whole country.
Credit binding to the pain point of pharmaceutical enterprises
The regulation of binding punishment for commercial bribery of the same medical agent and agent has stimulated the nerves of many pharmaceutical enterprises. In order to complete the sales target, agents will take out part of their profits to do marketing. Can our production enterprises manage what they do? They wont listen to you either. A sales manager of a pharmaceutical company in Hebei told the China times that he believed that it was open to question that pharmaceutical companies should be held responsible for the dishonesty of their employees and their agents.
In the past, pharmaceutical companies often turn a blind eye to the commercial bribery of their own products. Anyway, as long as the sales volume goes up, it is not my business how the pharmaceutical representatives and agents market. Once the east window incident occurs, it is very difficult to investigate the responsibility of pharmaceutical enterprises. Pharmaceutical bribery is the personal behavior of Representatives and agents has become a popular excuse in the industry.
Nowadays, the credit evaluation system of pharmaceutical enterprises makes the edge ball impossible to play, which binds pharmaceutical enterprises with pharmaceutical representatives and agents.
According to the operation specification, pharmaceutical enterprises promise to undertake the responsibility for breach of faith if their employees (including employment relationship, labor dispatch, purchase of services, principal-agent relationship, etc.), or distribution enterprises with principal-agent relationship, conduct dishonest behaviors, so as to gain or increase trading opportunities and competitive advantages of their own drugs or medical consumables. This means that in the future, once the pharmaceutical enterprises sell or the downstream distributors break faith, they will also directly track down the relevant enterprises and punish them.
According to the above-mentioned pharmaceutical enterprises, most of the thousands of pharmaceutical enterprises in China do not have sales teams. Instead, it is unrealistic for pharmaceutical enterprises to control the operation of agents by adopting the agent model.
Products in short supply may become weak points in evaluation
In recent years, the sales cost of pharmaceutical enterprises is not high, which is closely related to commercial kickbacks. According to the discretionary benchmark, in the future, the sales expense rate of pharmaceutical enterprises exceeds the industry average level by more than 100%, which will be recorded as a medium dishonest record. This also means that, in the past, pharmaceutical enterprises will stop their practice of marketing and even operating at a loss in order to seize the market.
However, those drugs or medical consumables with single supply structure and tense supply and demand situation may become the soft rib of credit evaluation. It includes the exclusive production and the monthly 3-day delivery rate of 3 consecutive months is less than 40%; it is irreplaceable, and stopping the supply will lead to the lack of clinical treatment means or the clinical treatment scheme can not be implemented; it has important therapeutic value, and stopping the supply will seriously affect the life safety of patients.
For the above-mentioned punishment of drugs or medical consumables involved, the operation specification points out that if it is not appropriate to suspend the qualification of online hanging, bidding or distribution, alternative measures can be taken based on the evaluation and confirmation of clinical opinions, such as delaying the disposal measures of suspending the qualification of hanging on the Internet, bidding or distribution until other enterprises can meet the supply requirements, or require the enterprise to issue the punishment according to the dishonest behavior Low historical price before death, stable supply of drugs or medical consumables. In addition, industry insiders pointed out that there are still key points missing from the two documents in terms of credit evaluation of pharmaceutical enterprises, such as the specification of quality level. If enterprises cut corners and produce substandard products for centralized purchase, how to determine the credit rating? In this regard, Zhou Shu also believes that it is necessary for the medical insurance bureau to formulate the medical price and bidding credit evaluation system for standardizing the participation of pharmaceutical enterprises in centralized purchase, but there are still some areas to be improved, which need to be run in and revised in the implementation of various provinces. Source: China Times Author: Yu Na, editor in charge: Wang Xiaowu_ NF
For the above-mentioned punishment of drugs or medical consumables involved, the operation specification points out that if it is not appropriate to suspend the qualification of online hanging, bidding or distribution, alternative measures can be taken based on the evaluation and confirmation of clinical opinions, such as delaying the disposal measures of suspending the qualification of hanging on the Internet, bidding or distribution until other enterprises can meet the supply requirements, or require the enterprise to issue the punishment according to the dishonest behavior Low historical price before death, stable supply of drugs or medical consumables.
In this regard, Zhou Shu also believes that it is necessary for the medical insurance bureau to formulate the medical price and bidding credit evaluation system for standardizing the participation of pharmaceutical enterprises in centralized purchase, but there are still some areas to be improved, which need to be run in and revised in the implementation of various provinces.